drugset / Trial / NCT02768077

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

NCT02768077

Phase 4 Unknown 100 enrolled Kuhnil Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This clinical study is a double-blind, randomized, placebo-controlled trial to investigate the effects of melatonin on the sleep disturbance symptoms of Parkinson's disease patients, symptoms which have a significant impact on the quality of life of these patients.

Timeline

Start
2016-01
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 2 mg Oral

Indications